실시간
FierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsEndpoints News#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetesClinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer PreventionClinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to DementiaEndpoints NewsIn Washington, biotech's China hawks are winning the conversationClinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future StrainsEndpoints NewsIndustry seeks more clarity on commissioner's voucher programBioWorldMoney raised by biopharma
10x Genomics Blog 2026년 1월 5일

Citi Maintains 10x Genomics(TXG.US) With Hold Rating - 富途牛牛

Citi Maintains 10x Genomics(TXG.US) With Hold Rating - 富途牛牛

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.